X0306 4/A 2020-11-23 2020-11-25 0 0001824893 Consonance-HFW Acquisition Corp. CHFW 0001824774 Consonance Life Sciences C/O CONSONANCE-HFW ACQUISITION CORP. 1 PALMER SQUARE, SUITE 305 PRINCETON NJ 08540 1 0 0 0 Class B Ordinary Shares 2020-09-04 4 A 0 3593750 0.007 A 3593750 D Class B Ordinary Shares 2020-10-08 4 D 0 718750 0.00 D 2875000 D Class B Ordinary Shares 2020-11-10 4 D 0 575000 0.00 D 2300000 D Class B Ordinary Shares 2020-11-18 4 S 0 30000 0.0109 D 2270000 D Class B Ordinary Shares 2020-11-18 4 S 0 30000 0.0109 D 2240000 D Class B Ordinary Shares 2020-11-18 4 S 0 30000 0.0109 D 2210000 D Class A Ordinary Shares 2020-11-23 4 A 0 410000 A 410000 D Warrant 11.50 2020-11-23 4 A 0 136667 A Class A Ordinary Shares 136667 136667 D Includes securities underlying the 410,000 private placement units of the Issuer purchased by the Reporting Person for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share. The Reporting Person is the record holder of the shares and warrants reported herein. The Reporting Person is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The warrants will expire five years after the completion of the Issuer's initial business combination. Includes 136,667 warrants underlying the units referred to in footnote 1. This Form 4 amendment is being filed to correct the original Form 4 filed on November 25, 2020. The original Form 4 had the incorrect transaction code, and did not include reporting of all of the required transactions. The Sponsor contributed these shares back to the Issuer for no consideration. Consonance Life Sciences, LLC ("Consonance Life Sciences") is governed by a board of managers consisting of Mitchell Blutt, Benny Soffer and Kevin Livingston. Dr. Blutt is the Chairman of the Board of Directors (the "Board") of Consonance-HFW Acquisition Corp. (the "Issuer"). By virtue of its representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Consonance Life Sciences is deemed a director by deputization of the Issuer. /s/ Kevin Livingston, Manager of Consonance Life Sciences, LLC 2021-05-19